A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

May 15, 2026 updated by: Bristol-Myers Squibb

Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France

The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

350

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: First line of the email MUST contain NCT # and Site #.

Study Contact Backup

  • Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  • Phone Number: 855-907-3286
  • Email: Clinical.Trials@bms.com

Study Locations

  • France
      • Amiens, France, 80054
        • Recruiting
        • CHU Amiens Picardie - Site Sud
        • Contact:
          • Ali Dadban, Site 060
          • Phone Number: 33322455841
      • Angers, France, 49100
        • Recruiting
        • Cabinet Médical Elisabeth Lion
        • Contact:
          • ANGELIQUE MARCHAND, Site 009
      • Argenteuil, France, 95107
        • Recruiting
        • CH Victor Dupouy
        • Contact:
          • EMMANUEL MAHE, Site 045
      • Argenteuil, France, 95107
        • Completed
        • Local Institution - 089
      • Arras, France, 62000
        • Recruiting
        • CH ARRAS
        • Contact:
          • CELINE DESVIGNES, Site 010
      • Bordeaux, France, 33200
        • Recruiting
        • Cabinet Dermatologie
        • Contact:
          • CHRISTELLE PRUVOST BALLAND, Site 048
      • Chalon-sur-Saône, France, 71100
        • Recruiting
        • Centre Hospitalier William Morey - Hématologie
        • Contact:
          • MARIE DHERS, Site 001
      • Clermont-Ferrand, France, 63000
        • Completed
        • Local Institution - 053
      • Dijon, France, 21000
        • Recruiting
        • CHU Dijon
        • Contact:
          • Camille LELEU, Site 002
          • Phone Number: 33 3 80 29 33 36
      • Dijon, France, 21000
        • Not yet recruiting
        • Local Institution - 077
        • Contact:
          • Site 077
      • La Tronche, France, 38700
        • Recruiting
        • CHU Grenoble Alps, Service de Dermatologie
        • Contact:
          • Julie Charles, Site 011
          • Phone Number: +33476766493
      • Le Mans, France, 72037
        • Not yet recruiting
        • Local Institution - 014
        • Contact:
          • Site 014
      • Le Puy-en-Velay, France, 43000
        • Recruiting
        • CH Emile Roux
        • Contact:
          • CHARLINE GARCIA, Site 074
      • Lens, France, 62307
        • Recruiting
        • Centre Hospitalier Lens
        • Contact:
          • ELENA KARIMOVA, Site 039
      • Marcq-en-Barœul, France, 59700
        • Recruiting
        • Centre de santé Filieris
        • Contact:
          • MARION STEFANSKI, Site 004
      • Montpellier, France, 34295
        • Recruiting
        • Hopital Saint Eloi
        • Contact:
          • CELINE GIRARD, Site 036
      • Nice, France, 06000
        • Recruiting
        • Tagast 41
        • Contact:
          • Abdallah Khemis, Site 012
          • Phone Number: +33492036225
      • Niort, France, 79021
        • Recruiting
        • Ch Georges Renon
        • Contact:
          • JEREMY GOTTLIEB, Site 008
      • Nîmes, France, 30900
        • Recruiting
        • Hopital Caremeau
        • Contact:
          • BLANCHE BERGERET, Site 062
      • Paris, France, 75012
        • Recruiting
        • Cabinet de dermatologie
        • Contact:
          • MATHILDE KEMULA, Site 073
      • Paris, France, 75012
        • Completed
        • Local Institution - 086
      • Périgueux, France, 24000
        • Recruiting
        • Hôpital Privé Francheville
        • Contact:
          • MARIE MASSON REGNAULT, Site 078
      • Roubaix, France, 59056
        • Recruiting
        • Centre Hospitalier de Roubaix
        • Contact:
          • SARAH JABRAN MAANAOUI, Site 047
      • Rouen, France, 76031
        • Completed
        • Local Institution - 031
      • Saint-Germain-en-Laye, France, 78100
        • Not yet recruiting
        • Local Institution - 065
        • Contact:
          • Site 065
      • Saint-Mandé, France, 94163
        • Recruiting
        • HIA Begin
        • Contact:
          • ANNE CLAIRE FOUGEROUSSE, Site 051
      • Saint-Maur-des-Fossés, France, 94100
        • Recruiting
        • Centre Dermatologique
        • Contact:
          • CHLOE CHARPENTIER, Site 072
      • Toulon, France, 83800
        • Recruiting
        • HIA Sainte Anne
        • Contact:
          • Thierry Boye, Site 055
          • Phone Number: 33483162916
      • Toulouse, France, 31059
        • Recruiting
        • Hôpital Larrey
        • Contact:
          • Carle Paul, Site 005
          • Phone Number: +33567778140
      • Vandœuvre-lès-Nancy, France, 54511
        • Recruiting
        • Hopitaux de Brabois
        • Contact:
          • EMMANUELLE MELGAR, Site 064
      • Villeurbanne, France, 69100
        • Recruiting
        • Medipole Hopital Mutualiste
        • Contact:
          • XAVIER MARCELLIN, Site 006
  • Switzerland
      • La Chaux-de-Fonds, Switzerland, 2300
        • Recruiting
        • Cabinet Medical
        • Contact:
          • Mireille Ruer-Mulard, Site 007
          • Phone Number: +33442800590
      • La Chaux-de-Fonds, Switzerland, 2300
        • Completed
        • Local Institution - 056
      • La Chaux-de-Fonds, Switzerland, 2300
        • Completed
        • Local Institution - 059

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Adult patients who have been diagnosed with moderate-to-severe plaque psoriasis and who intend to start deucravacitinib treatment in France

Description

Inclusion Criteria:

  • ≥18 years of age
  • Physician-reported diagnosis of moderate to severe plaque psoriasis
  • Be newly initiating deucravacitinib
  • Do not object to participate

Exclusion Criteria:

  • Currently participating in or planning to participate in an interventional clinical trial
  • Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Participants that have initiated deucravacitinib treatment
Drug: Deucravacitinib
As prescribed by treating clinician

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Physician's Global Assessment (PGA) 0/1 response
Time Frame: Baseline and at months 4, 12, 18 (optional), and 24
Baseline and at months 4, 12, 18 (optional), and 24
Dermatology Life Quality Index (DLQI) 0/1 response
Time Frame: Baseline and at months 4, 12, 18 (optional), and 24
Baseline and at months 4, 12, 18 (optional), and 24
Time from date of treatment initiation to date of discontinuation
Time Frame: Up to 24 months
Up to 24 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in percentage involved Body Surface Area (BSA) from start of deucravacitinib treatment
Time Frame: Baseline and at months 4, 12, 18 (optional), and 24
Baseline and at months 4, 12, 18 (optional), and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Itch
Time Frame: Baseline and months 1, 4, 12, 18 (optional) and 24
Baseline and months 1, 4, 12, 18 (optional) and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Skin pain
Time Frame: Baseline and months 1, 4, 12, 18 (optional) and 24
Baseline and months 1, 4, 12, 18 (optional) and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS)] - Fatigue
Time Frame: Baseline and months 1, 4, 12, 18 (optional) and 24
Baseline and months 1, 4, 12, 18 (optional) and 24
Physician's Global Assessment (PGA) score change from start of deucravacitinib treatment to follow-up
Time Frame: Baseline and at months 4, 12, 18 (optional), and 24
Baseline and at months 4, 12, 18 (optional), and 24
Dermatology Life Quality Index (DLQI) score of ≤5
Time Frame: Baseline and at months 1, 4, 12 18 (optional) and 24
Baseline and at months 1, 4, 12 18 (optional) and 24
Body Surface Area (BSA) of ≤ 3%
Time Frame: Baseline and at months 4, 12, 18 (optional), and 24
Baseline and at months 4, 12, 18 (optional), and 24
Body Surface Area (BSA) of ≤ 1%
Time Frame: Baseline and at months 4, 12, 18 (optional), and 24
Baseline and at months 4, 12, 18 (optional), and 24
Reasons for deucravacitinib treatment discontinuation
Time Frame: Up to 24 months
Up to 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bristol-Myers Squibb

Investigators

  • Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 29, 2025

Primary Completion (Estimated)

April 30, 2028

Study Completion (Estimated)

April 30, 2028

Study Registration Dates

First Submitted

November 20, 2024

First Submitted That Met QC Criteria

November 20, 2024

First Posted (Actual)

November 22, 2024

Study Record Updates

Last Update Posted (Actual)

May 18, 2026

Last Update Submitted That Met QC Criteria

May 15, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IM011-1127

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psoriasis

Clinical Trials on Deucravacitinib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe